title: Gonadotropin releasing hormone agonist therapy and its effect on bone mass.
abstract: The effects on bone mass of a 6 month therapeutic cycle with a gonadotropin releasing hormone agonist (GnRHa) were studied in 22 patients, ten affected by pelvic endometriosis and 12 by uterine fibroids. All patients were subjected to preliminary full examinations to confirm their diagnosis (laparoscopy for the endometriosis group and precise ultrasound volume measurements for uterine fibroids group). Before the beginning of treatment, bone mineral density (BMD) was measured in each patient both on the distal third of the forearm, with single-photon absorptiometry, and on the lumbar spine (L1-L4), with dual photon absorptiometry. The gonadotropin releasing hormone agonist used was buserelin. In the first week of therapy 0.5 mg of the drug was administered subcutaneously thrice daily. In the following 25 weeks the same drug was given intranasally, at a dosage of 300 micrograms again three times a day. Bone mass measurements, both at the peripheral and at the axial site, were repeated at the end of the 26-week therapeutic cycle and then again 6 months later. At the 26th week, a significant decrease of BMD was observed at both sites. The loss was 1.5% (p less than 0.05) on the lumbar spine, and 2.1% (p less than 0.05) on the radius. No bone mass restoration took place in the following 6 months. On the contrary, a less significant but discernible trend towards a further bone loss was apparent in the BMD values measured 6 months after the end of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: I Obstetrical and Gynaecological Department, University of Milano, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Nencioni
authors.forename: M
authors.initials: M
authors.lastname: Penotti
authors.forename: M
authors.initials: M
authors.lastname: Barbieri-Carones
authors.forename: S
authors.initials: S
authors.lastname: Ortolani
authors.forename: C
authors.initials: C
authors.lastname: Trevisan
authors.forename: F
authors.initials: F
authors.lastname: Polvani
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D015519:Bone Density / Q000187:drug effects*; D002064:Buserelin / Q000009:adverse effects / Q000494:pharmacology*; D004715:Endometriosis / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy
chemical_list: D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin